Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview

Tvardi Therapeutics

10/08/2026 12:23

Tvardi Therapeutics, Inc. TVRD.OQ TVRD.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Tvardi Therapeutics, Inc. is for a loss of 70 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Tvardi Therapeutics, Inc. is $9.50, about 408% above its last closing price of $1.87
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.74
-0.74
-0.73
Beat
1.9
Dec. 31 2026
-0.65
-0.78
Missed
-20.7
Sep. 30 2025
-1.01
-1.00
-0.59
Beat
41​
Jun. 30 2025
-0.65
-0.57
-1.00
Missed
-74.9
​​Mar. 31 2025
-0.35
-0.35
-3.22
Missed
-820
-5.04
​
Sep. 30 2024
-8.88
-8.28
Beat
6.8
Jun. 30 2024
-9.64
-9.86
-13.32
Missed
-35
This summary was machine generated August 10 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)